Author

Joshua P. Schrecker

Observed names: J Schrecker, Joshua Schrecker, Schrecker, Joshua

Observed institutions: Lincoln Memorial University, Tennessee Department of Health, University of Tennessee at Knoxville, The University of Texas Southwestern Medical Center

ORCID: 0000-0002-9731-123X

Observed ORCID: 0000-0002-9731-123X

OpenAlex ID: A5002262174

Widespread Distribution of Xylazine Detected Throughout the United States in Healthcare Patient Samples

2023 · Andrew C. Holt, David M. Schwope, et al. · Journal of Addiction Medicine · 47

Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age

2022 · Farid L. Khan, Jennifer L. Nguyen, et al. · JAMA Network Open · 40

PDF

Drug-Drug Interaction Assessment and Identification in the Primary Care Setting

2018 · John Peabody, Maria Czarina Acelajado, et al. · Journal of Clinical Medicine Research · 28

PDF

Validation of reduced S-gene target performance and failure for rapid surveillance of SARS-CoV-2 variants

2022 · Cyndi Clark, Joshua Schrecker, et al. · PLoS ONE · 18

PDF

Impact of Definitive Drug–Drug Interaction Testing on Medication Management and Patient Care

2018 · Renée J. G. Arnold, Jun Tang, et al. · Drugs - Real World Outcomes · 16

PDF

Withdrawal Signs and Symptoms Among Patients Positive for Fentanyl With and Without Xylazine

2024 · Ryan Alexander, Chinelo Agwuncha, et al. · Journal of Addiction Medicine · 14

Clinical Variation in the Treatment Practices for Medication Nonadherence, Drug–Drug Interactions, and Recognition of Disease Progression in Patients with Chronic Cardiometabolic Diseases: A Cross‐Sectional Patient Simulation Study among Primary Care Physicians

2022 · Czarlota Valdenor, Divya Ganesan, et al. · International Journal of Clinical Practice · 7

PDF

Randomized Trial to Improve Primary Care Patient Management and Patient Outcomes Using a Drug–Drug Interaction Test: Confirmation of the DECART Simulated Patient Clinical Utility Trial Results

2021 · John Peabody, Joshua Schrecker, et al. · Diagnostics · 7

PDF

Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care

2018 · John Peabody, Mary Tran, et al. · Journal of Clinical Medicine · 7

PDF

Impact of medication nonadherence and drug-drug interaction testing on the management of primary care patients with polypharmacy: a randomized controlled trial

2024 · Randy E. David, Kelsy Gibson Ferrara, et al. · BMC Medicine · 5

PDF

Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease

2023 · John W Peabody, Divya Ganesan, et al. · BMC Family Practice · 5

PDF

eP333: Tracking the emergence of SARS-CoV-2 variants of concern in vaccinated and unvaccinated patients

2022 · Alec Vest, Holly Houdeshell, et al. · Genetics in Medicine · 1

PDF

Surveillance and epidemiology of SARS-CoV-2 viral variants in the United States, May-October 2021 (Preprint)

2021 · Cyndi Clark, Tanya Singh, et al. · 1

Helping primary care providers recognize and respond to medication non-adherence and drug-drug interactions: A randomized-controlled clinical utility trial in a value-based care setting

2026 · Trever Burgon, David Paculdo, et al. · PLoS ONE

B-327 Evidence of Missed Novel Psychoactive Substances (NPS) in Unexpected Fentanyl Positives

2023 · G Campbell, J Schrecker, et al. · Clinical Chemistry

PDF

Characterization of drug-drug interactions in patients whose substance intake was objectively identified by detection in urine

2018 · Joshua Schrecker, Brandi Puet, et al. · Expert Opinion on Drug Metabolism & Toxicology

Impact of Urine Drug Testing Amongst Patients At Increased Risk of Drug-Drug Interactions

2018 · J Schrecker, C Hild, et al. · Value in Health

Works count: 21

Citation count: 196

H-index: 7

I10-index: 6